Search Result

Results for "

RAF Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Raf (145) Akt (8) Annexin A (1) Antibiotic (2) APC (1) Apoptosis (34) Atg8/LC3 (2) Aurora Kinase (1) Autophagy (29) Bacterial (1) Bcl-2 Family (3) Bcr-Abl (3) Beta-secretase (2) c-Fms (3) c-Kit (8) c-Met/HGFR (1) Cadherin (2) Caspase (2) Cathepsin (1) CDK (4) Cholinesterase (ChE) (2) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (1) Discoidin Domain Receptor (3) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (3) EGFR (6) Ephrin Receptor (3) ERK (18) Exosomes (1) FAK (1) Farnesyl Transferase (2) Ferroptosis (8) FGFR (7) FLT3 (9) G Protein-coupled Receptor Kinase (GRK) (1) Glutathione S-transferase (1) HBV (1) HCV (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) HIV (1) HSP (3) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (5) JAK (1) JNK (3) Keap1-Nrf2 (1) LXR (1) MAP3K (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (1) MEK (18) Microtubule/Tubulin (1) MMP (3) Molecular Glues (2) mTOR (1) NF-κB (1) P-glycoprotein (1) P2Y Receptor (1) p38 MAPK (13) PARP (2) PDGFR (11) PERK (3) Phosphatase (2) Phospholipase (1) PI3K (6) PKA (1) PROTACs (1) Ras (33) Reactive Oxygen Species (ROS) (3) Reference Standards (17) RET (13) Ribosomal S6 Kinase (RSK) (2) RIP kinase (1) Ser/Thr Protease (1) SHP2 (1) Src (6) STAT (4) TAM Receptor (1) TGF-β Receptor (1) Tie (7) TNF Receptor (3) Tyrosinase (1) VEGFR (29)
By Research Areas:	Cancer (177) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (11) Metabolic Disease (5) Neurological Disease (10)
Click Chemistry:	Alkynes (1)

187

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Raf

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14660

Dabrafenib 75+ Cited Publications GSK2118436A; GSK2118436	Raf	Cancer
Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of *Raf* with IC₅₀s of 5 nM and 0.6 nM for *C-Raf* and *B-Raf* ^V600E**, respectively .

HY-10331

Regorafenib 85+ Cited Publications BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-12057

Vemurafenib 100+ Cited Publications PLX4032; RG7204; RO5185426	Raf Autophagy	Cancer
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of *B-RAF* kinase, with IC₅₀s of 31 and 48 nM for RAF ^V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-15246

Tovorafenib 5+ Cited Publications TAK-580; MLN 2480; BIIB-024	Raf	Cancer
Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of *pan-Raf* kinase. Tovorafenib can be used for the study of glioma .

HY-10966

SB-590885 5+ Cited Publications	Raf Apoptosis	Neurological Disease Metabolic Disease Cancer
SB-590885 is a *BRAF/c-Raf* kinase inhibitor that selectively targets *B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits* the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

HY-14660A

Dabrafenib Mesylate 75+ Cited Publications GSK2118436 Mesylate; GSK 2118436B	Raf	Cancer
Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC₅₀s of 0.6 and 5.0 nM for Raf ^V600E and c-Raf, respectively.

HY-51424

PLX-4720 15+ Cited Publications	Raf	Cancer
PLX-4720 is a potent and selective inhibitor of *B-Raf* ^V600E with IC₅₀** of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-Raf ^V600E than wild-type B-Raf.

HY-158115

NST-628	Molecular Glues Raf MEK	Cancer
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC₅₀=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .

HY-109080

Belvarafenib 5 Publications Verification HM95573; GDC-5573; RG6185	Raf	Cancer
Belvarafenib (HM95573) is a potent and pan *RAF* (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC₅₀s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF ^v600E and C-RAF respectively .

HY-147268

Exarafenib RAF/KIN_2787	Raf p38 MAPK	Cancer
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity .

HY-50864

GDC-0879 4 Publications Verification	Raf	Cancer
GDC-0879 is a potent and selective *B-Raf* inhibitor with an IC₅₀ of 0.13 nM.

HY-10248

RAF265 5+ Cited Publications CHIR-265	Raf VEGFR Autophagy Apoptosis	Cancer
RAF265 is a potent and orally active *RAF/VEGFR2* inhibitor.

HY-101963

AD80	Raf Src Ribosomal S6 Kinase (RSK) RET	Cancer
AD80, a multikinase inhibitor, inhibits RET, *RAF,SRC*and S6K, with greatly reduced mTOR activity.

HY-N6670

Cefotetan	Antibiotic Raf ERK Ras MEK Bacterial	Infection
Cefotetan is a binding agent that targets *human Raf1 kinase inhibitor* protein (hRKIP*). Cefotetan binds to hRKIP, reduces the binding space between hRKIP and Raf1 kinase, relieves hRKIP's inhibition of the Ras/Raf1/MEK/ERK* signaling pathway, and enhances ERK phosphorylation. Cefotetan can be used to study diseases associated with dysregulated Ras/Raf1/MEK/ERK signaling pathways. Cefotetan is also a broad-spectrum antibacterial agent that disrupts cell wall synthesis by binding to bacterial penicillin-binding proteins (PBPs). It is used to study bacterial infections such as bone, skin, urinary tract, and lower respiratory tract .

HY-10331A

Regorafenib monohydrate 85+ Cited Publications BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1*, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-11004

AZ 628 10+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a *pan-Raf* kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for *B-Raf, B-RafV600E, and c-Raf-1*, respectively.

HY-10201S

Sorafenib-d3 1 Publications Verification Donafenib; Bay 43-9006-d₃	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

HY-14177

Raf inhibitor 1 3 Publications Verification	Raf	Cancer
Raf inhibitor 1 is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-100510

RAF709 5+ Cited Publications	Raf	Cancer
RAF709 is a potent, selective, and efficacious *RAF* inhibitor with IC₅₀s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively . Antitumor efficacy .

HY-13308

Regorafenib Hydrochloride 85+ Cited Publications BAY 73-4506 hydrochloride	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and *Raf-1* with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .

HY-15716

Kobe0065 4 Publications Verification	Ras Apoptosis	Cancer
Kobe0065 is a novel and effective inhibitor of *Ras-Raf* interaction*, competitively inhibiting* the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.

HY-12846

CCT196969	Raf	Cancer
CCT196969 is a pan-Raf inhibitor, which inhibits *B-Raf, BRaf ^V600E* and CRAF with IC₅₀s of 0.1, 0.04, and 0.01 μM, respectively.

HY-123673

MCP110 2 Publications Verification	Ras Raf	Cancer
MCP110 is an inhibitor of *Ras/Raf-1* interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors .

HY-12787

L-779450 1 Publications Verification	Raf Autophagy	Cancer
L-779450 is a potent and selective *B-Raf* kinase inhibitor with a K_d of 2.4 nM.

HY-10247

BRAF inhibitor 1 Publications Verification	Raf	Cancer
BRAF inhibitor (Compound P-0850) is a *B-Raf* inhibitor with anti-tumor activity .

HY-138294

RAS/RAS-RAF-IN-1 2 Publications Verification	Ras Raf	Cancer
RAS/RAS-RAF-IN-1 is a potent RAS and *RAS-RAF* inhibitor. RAS/RAS-RAF-IN-1 has a K_D of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity .

HY-15717

Kobe2602 1 Publications Verification	Ras	Cancer
Kobe2602 is a *Ras-Raf* interaction** inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity .

HY-10201S2

Sorafenib-13C,d3 1 Publications Verification Bay 43-9006-¹³C,d₃	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10201R

Sorafenib (Standard) Bay 43-9006 (Standard)	Reference Standards Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Standard) is the analytical standard of Sorafenib. This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) is a potent and orally active *Raf* inhibitor with IC₅₀s of 6 nM and 20 nM for *Raf-1* and *B-Raf, respectively. Sorafenib is a multikinase inhibitor* with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-I0678

Regorafénib N-oxyde (M2)	Drug Metabolite PDGFR	Cancer
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-109574

Raf inhibitor 2 1 Publications Verification	Raf	Cancer
Raf inhibitor 2 is a potent raf kinase (IC₅₀<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research .

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of *RAF* kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-77113

B-Raf IN 11	Raf	Cancer
B-Raf IN 11 is a *B-Raf* ^V600E mutant kinase inhibitor with an IC₅₀ of 76 nM, and exhibits an IC₅₀ of 238 nM against wild-type *B-Raf* kinase. B-Raf IN 11 inhibits the kinase activities of *B-Raf* ^V600E mutant and wild-type *B-Raf* kinase. B-Raf IN 11 is applicable to relevant research on colorectal cancer .

HY-18227

B-Raf IN 1	Raf	Cancer
B-Raf IN 1 is a potent and selective *B-Raf* kinase inhibitor with an IC₅₀ of 24 nM.

HY-N13009

MO-2097	Raf HIF/HIF Prolyl-Hydroxylase ERK MEK Reactive Oxygen Species (ROS) Apoptosis Caspase	Cancer
MO-2097 is a *RAF-1/HIF-1α* inhibitor. MO-2097 induces *RAF-1* destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the *RAF/MEK/ERK* signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer .

HY-W013411A

Locostatin 3 Publications Verification UIC-1005	Raf G Protein-coupled Receptor Kinase (GRK)	Cancer
Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-14947

Balamapimod MKI 833	MEK	Cancer
Balamapimod (MKI 833) is a reversible *Ras/Raf/MEK* inhibitor with potential anti-tumor activity.

HY-177511

KRAS G12D-IN-30	Ras p38 MAPK Raf MEK ERK	Cancer
KRAS G12D-IN-30 (Compound 4) is a KRAS inhibitor. KRAS G12D-IN-30 inhibits the activation of the downstream MAPK signaling cascade (Raf1-MEK-ERK) by blocking the activity of the KRAS G12 mutant. KRAS G12D-IN-30 can be used for the research of cancer .

HY-148059

Uplarafenib B-RAF IN 10	Raf	Cancer
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC₅₀ between 50 and 100 nM. Uplarafenib shows antitumor activity .

HY-10201S1

Sorafenib-d4 Bay 43-9006-d₄	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₄ (Bay 43-9006-d₄) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-159534

Flezurafenibum FlezuRAFenib	Raf	Cancer
Flezurafenibum (Flezurafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, with antineoplastic effect .

HY-126298

RAF mutant-IN-1	Raf	Cancer
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC₅₀ values of 21 nM, 30 nM and 392 nM for C-RAF ^340D/Y341D, B-RAF ^V600E and B-RAF ^WT, respectively .

HY-15198

KG5	Raf PDGFR FLT3 c-Kit	Cancer
KG5 is an orally active dual PDGFRβ and *B-Raf* allosteric inhibitor. KG5 also inhibits Flt3, KIT and *c-Raf*. KG5 has anticancer, antiangiogenic activities .

HY-159508

Brimarafenib	Raf	Cancer
Brimarafenib is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor wtih antineoplastic effect .

HY-14177A

Raf inhibitor 1 dihydrochloride 3 Publications Verification	Raf	Cancer
B-Raf inhibitor 1 dihydrochloride is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-W013411

(E/Z)-Locostatin (E/Z)-UIC-1005	Raf	Cancer
(E/Z)-Locostatin ((E/Z)-UIC-1005) is a racemic of Locostatin. Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .

HY-14660S

Dabrafenib-d9 GSK2118436A-d₉; GSK2118436-d₉	Isotope-Labeled Compounds Raf	Cancer
Dabrafenib-d₉ is the deuterium labeled Dabrafenib. Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC₅₀s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively .

HY-164492

LSN3074753	Raf	Cancer
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and *Raf* dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or *RAF* dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .

HY-19343

XL-281 BMS-908662	Raf	Cancer
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC₅₀s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity .

Cat. No.	Product Name

HY-L010

MAPK Compound Library

1,063 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 1,063 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Cat. No.	Product Name	Target	Research Area

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of *RAF* kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-P10051

Cyclorasin 9A5	Ras Raf	Cancer
Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the *Ras-Raf* protein interaction with an IC₅₀ of 120 nM .

HY-P10051A

Cyclorasin 9A5 TFA	Ras Raf	Cancer
Cyclorasin 9A5 TFA is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the *Ras-Raf* protein interaction with an IC₅₀ of 120 nM .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6796

Manumycin A 2 Publications Verification	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Disease Research Anticancer Disease Research Fields Other Antibiotics Source Classification	Antibiotic Exosomes Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3
Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the *Ras/Raf/ERK1/2* signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species (ROS)
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N0226

Epiberberine	Alkaloids Structural Classification Coptis chinensis Franch. Ranunculaceae Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-N10503

Norartocarpetin	Flavonoids Flavones Plants Moraceae	Tyrosinase Ras Raf MAPKAPK2 (MK2) Apoptosis
Norartocarpetin is a tyrosinase inhibitor. Norartocarpetin has strong tyrosinase inhibitory activity with an IC₅₀ value of 0.47 μM. Norartocarpetin as an antibrowning agent can be used for the research of food systems. Norartocarpetin also has a significant anticancer activity in lung carcinoma cells (NCI-H460) with an IC₅₀ value of 22 μM. Norartocarpetin has antiproliferative effects are mediated via targeting Ras/Raf/MAPK signalling pathway, mitochondrial mediated apoptosis, S-phase cell cycle arrest and suppression of cell migration and invasion in human lung carcinoma cells .

HY-N13009

MO-2097	Phenols Polyphenols Morus alba L. Plants Moraceae Source Classification	Raf HIF/HIF Prolyl-Hydroxylase ERK MEK Reactive Oxygen Species (ROS) Apoptosis Caspase
MO-2097 is a *RAF-1/HIF-1α* inhibitor. MO-2097 induces *RAF-1* destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the *RAF/MEK/ERK* signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer .

HY-N3634

Corylifol C	Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-N15264

Azaspirene (-)-Azaspirene	Natural Products Microorganisms Source Classification	VEGFR Raf
Azaspirene ((-)-Azaspirene) is an angiogenesis and *Raf-1* activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and *Raf-1* activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2) .

HY-W065835

2-Bromoaldisine	Alkaloids Pyrrole Alkaloids Marine natural products Source Classification	HIV
2-Bromoaldisine is a pyrrole alkaloid that can be isolated from the Red Sea: marine sponge Stylissa carter. 2-Bromoaldisine inhibits HIV-1 vector infection. 2-Bromoaldisine inhibits *Raf/MEK/MAPK* pathway .

HY-119925

Amaralin	Structural Classification Prosopis juliflora (Sw.) DC. Terpenoids Sesquiterpenes Plants Compositae Source Classification	Drug Intermediate
Amaralin is a sesquiterpene lactone with analgesic activity, which exists in the leaves and stems of Helenium amarum (Raf.) H. Rock. When administered subcutaneously, Amaralin produces analgesic effects in the mouse tail-flick test. When administered subcutaneously, Amaralin inhibits acetic acid-induced writhing syndrome in mice. Amaralin can be used for pain-related research .

Cat. No.	Product Name	Chemical Structure

HY-10201S

Sorafenib-d3 1 Publications Verification
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10201S1

Sorafenib-d4
Sorafenib-d₄ (Bay 43-9006-d₄) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2 . Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .

HY-14660S

Dabrafenib-d9
Dabrafenib-d₉ is the deuterium labeled Dabrafenib. Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC₅₀s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively .

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-51424S

PLX-4720-d7
PLX-4720-d₇ is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC₅₀?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf .

HY-10201S4

Sorafenib-d3 tosylate

Sorafenib-d₃ (Donafenib-d₃) tosylate is the deuterium labeled Sorafenib (HY-10201). Sorafenib is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib-d3tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib-d3tosylate induces autophagy and apoptosis. Sorafenib-d3tosylate has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-12057S

Vemurafenib-d5
Vemurafenib-d₅ is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC₅₀s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-12057S1

Vemurafenib-d7
Vemurafenib-d₇ is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC₅₀s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

Host:	Rabbit (2)
Reactivity:	Human (2) Rat (2) Mouse (2)
Application:	IHC-P (2) IP (2) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82124

	RKIP Antibody (YA1869) PEBP1; PBP; PEBP; Phosphatidylethanolamine-binding protein 1; PEBP-1; HCNPpp; Neuropolypeptide h3; Prostatic-binding protein; RAF kinase Inhibitor protein; RKIP	WB, IHC-P, IP	Human, Mouse, Rat
	RKIP Antibody (YA1869) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RKIP.

HY-P82124A

	RKIP Antibody (YA1869)(PBS only) PEBP1; PBP; PEBP; Phosphatidylethanolamine-binding protein 1; PEBP-1; HCNPpp; Neuropolypeptide h3; Prostatic-binding protein; RAF kinase Inhibitor protein; RKIP	WB, IHC-P, IP	Human, Mouse, Rat
	RKIP Antibody (YA1869) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RKIP.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-134813

MRTX1133 45+ Cited Publications		Alkynes
MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks